

Eosinophil-derived neurotoxin as a biomarker for disease severity and relapse in recalcitrant atopic dermatitis

Hwan Soo Kim, MD, PhD; Ji Hye Kim, MD; Yu Mi Seo, MD; Yoon Hong Chun, MD, PhD; Jong-seo Yoon, MD, PhD; Hyun Hee Kim, MD, PhD; Joon Sung Lee, MD, PhD; Jin Tack Kim, MD, PhD

Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea

ARTICLE INFO

Article history:

Received for publication March 31, 2017.

Received in revised form June 12, 2017.

Accepted for publication June 28, 2017.

ABSTRACT

Background: Eosinophils are encountered in many skin diseases, but the role of eosinophils in atopic dermatitis (AD) remains uncertain.

Objective: To examine the role of serum eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), and total IgE as a biomarker of disease severity and relapse in severe recalcitrant AD.

Methods: We enrolled 99 patients with AD: 37 with severe recalcitrant AD, 20 with severe AD, and 42 with mild to moderate AD. We examined the difference in serum level of total IgE, ECP, and EDN between the groups and whether any correlation existed between disease severity and ECP or EDN. Lastly, difference in levels of ECP or EDN between those who experienced relapse was examined in the severe recalcitrant group.

Results: Serum levels of total IgE, ECP, and EDN were significantly higher in the severe recalcitrant AD group and severe AD group compared with the mild to moderate AD group. No significant difference was found in serum levels of total IgE, ECP, and EDN between the severe recalcitrant group and severe group. EDN had a significant positive correlation with the SCORing Atopic Dermatitis. No significant correlation was found between EDN and ECP. In the severe recalcitrant group, 29.7% of patients experienced relapse, and EDN was significantly higher in those who experienced relapse. The cutoff value of EDN for predicting relapse was 64.5.

Conclusion: EDN correlated with the disease severity of AD. EDN may predict relapse in severe recalcitrant AD. The EDN serum level could be considered a candidate molecule as a clinical biomarker for evaluating AD disease activity and a predictor of relapse.

© 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Introduction

Eosinophils are encountered in many skin diseases, but their functional role remains unclear. There is evidence that eosinophils might contribute to pathogen defense, regulate inflammatory responses, and induce fibrosis/remodeling in skin disease.^{1,2}

In atopic dermatitis (AD), tissue eosinophilia is a typical finding, often associated with increased blood eosinophil levels and correlating with disease severity.³ In the skin, eosinophils as part of the perivascular inflammatory infiltrate and extracellular granule protein deposits have been identified.^{4,5}

Eosinophils can serve as major effector cells, inducing tissue damage and dysfunction by releasing granule proteins, including eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), inflammatory lipid mediators, and mitochondrial DNA.⁵ ECP

and EDN are known to reflect the activity of eosinophils.² In this regard, AD is characterized by blood and tissue eosinophilia and increased ECP that correlates with the disease activity in patients.⁶

So far, the activity of eosinophils in AD remains uncertain. It seems possible that eosinophils contribute to host defense against invading microbes through the defective skin barrier by generating extracellular DNA traps, regulating the immune response, and/or remodeling.^{7–9}

Studies have focused on eosinophil and serum ECP as reflecting disease severity in AD, but studies on eosinophils, serum ECP, and serum EDN in severe recalcitrant AD that requires systemic immunosuppressant are lacking.^{3,6} In this study, we aimed to examine the level of eosinophil granule protein, ECP, and EDN, which are known to reflect activity of eosinophils in AD.

Methods

Patients

Ninety-nine children with AD (mean [SD] age, 6.0 [4.9] years), defined according to the Hanifin and Rajka criteria, were included in the study. Severity of AD was assessed by SCORing Atopic

Reprints: Jin Tack Kim, MD, PhD, Department of Pediatrics, College of Medicine, The Catholic University of Korea, 271, Cheonbo-ro, Uijeongbu-si, Gyeonggi-do 11765, Republic of Korea; E-mail: jintackk@catholic.ac.kr.

Drs H.S. Kim, J.H. Kim, and Y.M. Seo contributed equally to this work.

Disclosures: Authors have nothing to disclose.

<http://dx.doi.org/10.1016/j.anai.2017.06.022>

1081-1206/© 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Dermatitis (SCORAD) on visiting the clinic. Patients were classified as follows: patients with SCORADs greater than 50 and those who needed systemic immunosuppressive treatment because of poor response to topical steroids were defined as having severe recalcitrant AD, patients with SCORADs greater than 50 and those who had good response to topical steroids were defined as having severe AD, and those with SCORADs less than 50 were defined as having mild to moderate AD. No patients had SCORADs less than 50 and required systemic immunosuppressive treatment. We included 37 consecutive patients who were treated with cyclosporine for severe recalcitrant AD, 20 consecutive patients with severe AD, and 42 consecutive patients with mild to moderate AD, who were treated with topical steroids. Twenty individuals were included as a healthy control group, selected from patients who visited the well-child clinic and those who visited Uijeongbu St Mary's hospital for minor surgery with no history of AD and available measured serum total IgE levels. Patients with a history of treatment with systemic corticosteroids, cytotoxic agents, or phototherapy within 2 weeks before entry, previous treatment with cyclosporine, abnormal renal or liver function, and hypertension were excluded. Blood samples were obtained before initiation of treatment. This research was approved by the Uijeongbu St. Mary's Hospital Institutional Review Board. Written informed consent was obtained from parents or guardians; assent was obtained from invited children.

Treatment With Cyclosporine

All patients given a dose of 5.0 mg/kg of cyclosporine (Sandimmun Neoral soft gelatine capsules or oral solution, Novartis Pharmaceuticals Ltd, Seoul, Korea) per day, which was reduced to 1.5 to 3.0 mg/kg after 4 weeks according to response. Treatment was stopped at week 12 after a 4-week dose-tapering period, and treatment was discontinued in all patients who had not already had treatment discontinued. Treatment was restarted at 5.0 mg/kg when patients relapsed or when the investigator or patient believed that further systemic therapy was required. Patients were followed for up to 1 year. Use of topical corticosteroids was allowed throughout the study, with no restriction on the potency. The dose of cyclosporine was reduced by 25% in the following cases: those with an increase of serum creatinine of 30% to 50% above baseline, those with significant hypertension after 2 consecutive visits, and those with an increase of more than 3 times the upper normal limit for any liver function parameter. The dose of cyclosporine was reduced by 50% if the increase in creatinine was 50% to 100% greater than baseline, and the patient was withdrawn from the trial if the increase exceeded 100%.

Measurement of Blood Eosinophils, Serum ECP, and EDN

The NE-8000 system (Sysmax, Kobe, Japan) was used to count white blood cells and eosinophils automatically in peripheral blood. Blood samples for determination of serum ECP and EDN were drawn into vacuum tubes (Vacutainer SST, Becton Dickinson, Mountain View, California) and allowed to clot at room temperature for 60 minutes, followed by centrifugation at 1300g for 10 minutes at 4°C. Each sample was aliquoted into a fresh plastic tube and stored at –20°C until the assays for serum ECP and EDN were performed. Serum ECP was measured with the CAP radioallergosorbent technique (UniCAP. Pharmacia and Upjohn, Uppsala, Sweden). Sensitivity for ECP was 2.00 ng/mL, and the normal serum ECP range was 4 to 20 ng/mL. Serum EDN was measured with an enzyme-linked immunosorbent assay kit (MBL, Nagoya, Japan) according to the manufacturer's instructions. Briefly, 100 μ L of each sample was transferred to a microwell coated with antihuman EDN antibody and incubated at room temperature for 1 hour. After the sample was rinsed with wash solution, 100 μ L of conjugate solution was added to the wells, and incubation was continued at room temperature for an

additional hour. After another washing, 3,3', 5,5'-tetramethylbenzidine chromogen solution (100 μ L per well) was added and allowed to incubate for 10 minutes at room temperature. Enzyme reactions were stopped with 0.2 M sulfuric acid (100 μ L per well) and the absorbance measured at 450 nm with a microplate reader within 30 minutes of stopping. According to the manufacturer's data sheet, the sensitivity for EDN was 0.62 ng/mL, and the linear range was 0.62 to 40 ng/mL. Values that exceeded the linear range were calculated after dilution. All assays were performed in duplicate for each sample, with the mean values reported here.

Measurement of Total IgE

Total IgE levels were measured with the ImmunoCAP immuno-fluorimetric assay (Thermo Fisher Scientific, ImmunoDiagnostics, Uppsala, Sweden). Measures of total IgE levels were expressed in international units per unit volume (1 IU = 2.4 ng). The measuring range of total IgE was 2 to 5,000 IU/mL.

Statistical Analysis

Statistical analyses were performed using SPSS software, version 20.0 (IBM Inc, Armonk, NY). All continuous variables are expressed as mean (SD) and categorical variables as number (percentage). The Shapiro-Wilk test was used to verify normality of nonparametric variables. The Bonferroni method was used for post hoc analysis. A linear regression analysis was applied for correlations between SCORAD and laboratory variables of the patients. The *t* test was used to compare the differences in laboratory findings in those who experienced relapse and those who did not. A receiver operating characteristic (ROC) curve was constructed, and the area under the curve for each parameter was compared with 0.5 to estimate the optimal cutoff levels for detecting relapse of severe recalcitrant AD. Sensitivity, specificity, positive predicted value, and negative predicted value were calculated. Statistical significance was defined at $P < .05$ in a 2-tailed test.

Results

Characteristics of Patients

A total of 119 patients were included in the study, and their characteristics are summarized in Table 1. There were 37 patients in the severe recalcitrant group, 20 patients in the severe group, 42 patients in the mild to moderate group, and 20 in the control group. Sex, age, and white blood cell count showed no significant difference, but SCORAD was significantly higher in the severe group compared with the mild to moderate group. Total IgE was significantly higher in the severe group compared with the control group. In regard to the number of eosinophils and eosinophil granule protein levels, the number of eosinophils was significantly higher in the severe group and mild to moderate group compared with control group. EDN was significantly higher in the severe group compared with mild to moderate group and control group. Likewise, ECP was significantly higher in the severe group and mild to moderate group compared with the control group (Table 1).

Correlation of Initial Total IgE, Blood Eosinophil Counts, ECP, and EDN With Disease Severity

SCORAD had significant correlations with EDN ($r = 0.365$, $P < .001$). Total IgE levels, blood eosinophil counts, and ECP failed to show significant correlations with SCORAD ($r = 0.154$, $P < .001$, $r = .081$, $P = .004$, and $r = 0.087$, $P = .003$, respectively) (Fig 1).

Correlation of EDN With ECP

EDN and ECP failed to show a significant correlation with each other ($r = 0.131$, $P < .001$) (Fig 2).

Table 1
Patient Characteristics

Characteristic	Severe recalcitrant AD (n = 37)	Severe AD (n = 20)	Mild to moderate AD (n = 42)	Control (n = 20)	P value
Male, n	22	10	33	11	.65
Age, y	6.5 (5.2)	8.4 (5.5)	4.5 (4.0)	4.0 (3.7)	.006
SCORAD	65.5 (11.6)	64.1 (11.7)	20.8 (8.9)	NA	<.001
WBCs, $\times 10^4$	10,175.4 (5,189.0)	9,750.0 (3,560.0)	9,923.6 (3,356.2)	10,115.5 (3,330.5)	.98
Total IgE, IU/mL	1,480.7 (1,659.4)	1,469.0 (1,670.6)	305.2 (509.4)	44.9 (34.4)	<.001 ^a
Eosinophils, $\times 10^4$	872.9 (997.2)	813.6 (708.5)	488.8 (526.4)	140 (102.1)	.001 ^b
EDN, ng/mL	54.1 (24.4)	56.7 (24.1)	25.7 (17.8)	13.2 (9.6)	<.001 ^c
ECP, ng/mL	72.0 (55.7)	68.3 (52.2)	47.6 (43.1)	12.3 (8.0)	<.001 ^d

Abbreviations: AD, atopic dermatitis; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; NA, not applicable; SCORAD, SCORing Atopic Dermatitis; WBCs, white blood cells.

NOTE. Data are presented as mean (SD) unless otherwise indicated.

^a $P < .05$: severe recalcitrant AD vs mild to moderate AD, severe recalcitrant AD vs control, severe AD vs mild to moderate AD, and severe AD vs control.

^b $P < .05$: severe recalcitrant AD vs control and severe AD vs control.

^c $P < .05$: severe recalcitrant AD vs mild to moderate AD, severe recalcitrant AD vs control, severe AD vs mild to moderate AD, and severe AD vs control.

^d $P < .05$: severe recalcitrant AD vs control, severe AD vs control, and mild to moderate AD vs control.

Comparison of Initial SCORAD, ECP, and EDN Between Relapse and No Relapse

In the severe recalcitrant AD group, 11 patients (29.7%) experienced relapse. No significant difference was observed in SCORAD ($P = .052$), ECP ($P = .56$), and total IgE ($P = .70$) between patients who experienced relapse and those who did not. EDN was significantly higher in those who experienced relapse than those who did not ($P < .001$) (Table 2).

Predictive Value of EDN to Predict Relapse in Severe Recalcitrant AD

ROC curves were constructed to determine the cutoff levels of EDN for predicting relapse in severe recalcitrant AD. The area under curve was 0.874 (Fig 3). The cutoff value for predicting relapse in severe recalcitrant AD was 64.5 ng/mL, with a sensitivity of 72.7%, a specificity of 76.9%, a positive predictive value of 72.7%, and a negative predictive value of 23.1%. With a cutoff value of 64.5 ng/mL,

8 patients had titers higher than 64.5 ng/mL in the relapse group (data not shown).

Discussion

In this study, we found that level of total IgE, number of eosinophils, level of ECP, and level of EDN were significantly higher in the severe recalcitrant AD group and severe AD group compared with the mild to moderate AD group. Only EDN correlated with SCORAD. Lastly, 29.7% of patients with severe recalcitrant AD had relapse after treatment with cyclosporine, and EDN was significantly higher in those who experienced relapse than those who did not.

Before treatment, the number of eosinophils had a significant positive correlation with ECP and EDN (data not shown). This finding indicated that our measurement of ECP and EDN could be considered to be reliable. Eosinophils are known to release granule proteins, including ECP and EDN.⁵

Level of total IgE, number of eosinophils, and levels of ECP and EDN were significantly higher in the severe recalcitrant AD group




Figure 1. Correlation of SCORAD with (A) total IgE, (B) blood eosinophil counts, (C) eosinophil-derived neurotoxin (EDN), and (D) eosinophil cationic protein ECP.




Figure 2. Correlation of eosinophil-derived neurotoxin (EDN) with eosinophil cationic protein (ECP).

and severe AD group compared with the mild to moderate AD group and control group. Eosinophils are known to be involved in allergic and infectious immune responses.^{10–14} The regulative potential of eosinophils in both innate and adaptive immune responses has been realized during the past decade and became the target for therapeutic strategies in allergic diseases.¹¹ Eosinophils are frequently increased in childhood asthma and AD.^{15–18} Similar findings from our study have been observed in previous studies; patients with AD and eosinophilia (>500 cells/ μ L) had high symptom scores and long duration of the disease.¹⁵

Other than eosinophils, various biomarkers, such as total IgE, ECP, soluble interleukin (IL) 2 receptor, IL-17, IL-23, endothelin 1, thymus and activation-regulated chemokine, and clusterin have been studied, which reflected the severity of AD.^{19–23} Two studies reported that serum EDN²⁴ and urinary EDN²⁵ acted as markers for disease severity in AD. In concordance with previous studies, the current study found that EDN correlated with SCORAD. Our finding suggests that eosinophils and eosinophil granule proteins might play a differential role in severe recalcitrant AD compared with mild to moderate AD. Further supporting the role of EDN in AD, cyclosporine is known to be an immunomodulant. Cyclosporine lowers the level of serum IL-8, a cytokine that plays a crucial role in eosinophil activation and migration, in accordance with the decrease in the eosinophil count.^{26–28} A reason for poor correlation with SCORAD and ECP might be because ECP was measured on visiting the outpatient clinic, which meant that ECP was not measured at a fixed time. ECP is known to have poor consistency with diurnal variation.²⁹ We examined the correlation between EDN and ECP, but there was no significant correlation. This finding also might be because ECP has a diurnal variation.

Relapse is known to be common in children treated with cyclosporine. In our study, 11 patients (29.7%) experienced relapse




Figure 3. Receiver operating characteristic (ROC) curve of eosinophil-derived neurotoxin for predicting relapse in severe recalcitrant atopic dermatitis.

after treatment with cyclosporine. This relapse rate in children was higher than 20% and lower than 41.7% reported by Bunikowski et al.³⁰ and Sibbald et al.,³¹ respectively.^{30,31} We examined whether SCORAD, ECP, EDN, or total IgE levels were different between those who experienced relapse and those who did not, and EDN produced a significant difference. We used ROC analysis to determine the cutoff value of EDN to predict relapse and found that it was 64.5 ng/mL. To the best of our knowledge, this is the first study to examine whether any laboratory data act as predictive markers for relapse. Further studies with a larger study population investigating the role of EDN or discovering other novel biomarkers for relapse appear to be worthy.

A limitation of our study is our failure to measure cytokines, such as IL-4 and IL-5, which are known to specifically promote the development, differentiation, and activation of eosinophils.^{32,33} Secondly, as mentioned earlier, ECP was measured on visiting the outpatient clinic, which means that ECP was not measured at a fixed time. Hence, interpretation of our data must be done carefully.

In conclusion, EDN reflects disease severity in AD and may predict relapse in severe recalcitrant AD. The serum level of EDN could be considered as a clinical biomarker for evaluating disease activity of AD. Further studies may reveal novel biomarkers that can more accurately predict relapse in severe recalcitrant AD than serum levels of EDN.

Acknowledgments

We acknowledge the efforts of K.Y. Lee, MD, and M.H. Lee, MD, in the collection and analysis of data for this study.

References

- [1] Simon D, Simon HU, Yousefi S. Extracellular DNA traps in allergic, infectious, and autoimmune diseases. *Allergy*. 2013;68:409–416.
- [2] Yousefi S, Simon D, Simon HU. Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. *Curr Opin Immunol*. 2012;24:736–739.

Table 2

Comparison of Mean (SD) SCORAD, EDN, ECP, and Total IgE Values Between Patients With and Without Relapse in Severe Recalcitrant Atopic Dermatitis

Variable	Relapse (n = 11)	No relapse (n = 26)	P value
SCORAD	71.5 (3.3)	63.0 (2.2)	.052
EDN, ng/mL	78.6 (5.6)	46.6 (4.2)	<.001
ECP, ng/mL	79.5 (18.1)	67.9 (10.4)	.56
Total IgE, IU/mL	1,645.1 (546.0)	1,411.7 (318.4)	.70

Abbreviations: EDN, eosinophil-derived neurotoxin; ECP, eosinophil cationic protein; SCORAD, SCORing Atopic Dermatitis.

- [3] Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. *Br J Dermatol*. 2001;145:720–729.
- [4] Leiferman KM, Ackerman SJ, Sampson HA, et al. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. *N Engl J Med*. 1985;313:282–285.
- [5] Soragni A, Yousefi S, Stoeckle C, et al. Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation. *Mol Cell*. 2015;57:1011–1021.
- [6] Czech W, Krutmann J, Schopf E, Kapp A. Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. *Br J Dermatol*. 1992;126:351–355.
- [7] Roth N, Stadler S, Lemann M, et al. Distinct eosinophil cytokine expression patterns in skin diseases – the possible existence of functionally different eosinophil subpopulations. *Allergy*. 2011;66:1477–1486.
- [8] Morshed M, Yousefi S, Stockle C, Simon HU, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. *Allergy*. 2012;67:1127–1137.
- [9] Simon D, Aeberhard C, Erdemoglu Y, Simon HU. Th17 cells and tissue remodeling in atopic and contact dermatitis. *Allergy*. 2014;69:125–131.
- [10] Lowell FC. Clinical aspects of eosinophilia in atopic disease. *JAMA*. 1967;202:875–878.
- [11] Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. *Nat Rev Drug Discov*. 2013;12:117–129.
- [12] Roufosse F, Weller PF. Practical approach to the patient with hyper-eosinophilia. *J Allergy Clin Immunol*. 2010;126:39–44.
- [13] Adamko D, Lacy P, Moqbel R. Eosinophil function in allergic inflammation: from bone marrow to tissue response. *Curr Allergy Asthma Rep*. 2004;4:149–158.
- [14] Akuthota P, Weller PF. Eosinophils and disease pathogenesis. *Semin Hematol*. 2012;49:113–119.
- [15] Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. *Clin Rev Allergy Immunol*. 2011;41:298–310.
- [16] Gerritsen J, Koëter GH, de Monchy JG, Knol K. Allergy in subjects with asthma from childhood to adulthood. *J Allergy Clin Immunol*. 1990;85:116–125.
- [17] Toma T, Mizuno K, Okamoto H, et al. Expansion of activated eosinophils in infants with severe atopic dermatitis. *Pediatr Int*. 2005;47:32–38.
- [18] Wu KG, Li TH, Chen CJ, Cheng HI, Wang TY. Correlations of serum Interleukin-16, total IgE, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis. *Int J Immunopathol Pharmacol*. 2011;24:15–23.
- [19] Thijs JL, Nierkens S, Herath A, et al. A panel of biomarkers for disease severity in atopic dermatitis. *Clin Exp Allergy*. 2015;45:698–701.
- [20] Leonardi S, Cuppari C, Manti S, et al. Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis syndrome (AEDS): Association with clinical severity and phenotype. *Allergy Asthma Proc*. 2015;36:74–81.
- [21] Tsybikov NN, Petrisheva IV, Kuznik BI, Magen E. Plasma endothelin-1 levels during exacerbation of atopic dermatitis. *Allergy Asthma Proc*. 2015;36:320–324.
- [22] Song TW, Sohn MH, Kim ES, Kim KW, Kim KE. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis. *Clin Exp Allergy*. 2006;36:346–351.
- [23] Sol IS, Kim YH, Lee KE, et al. Serum clusterin level in children with atopic dermatitis. *Allergy Asthma Proc*. 2016;37:335–339.
- [24] Lee KY, Cho KJ, Kim YT, Kim JT. Serum eosinophil-derived neurotoxin in childhood atopic dermatitis: a useful marker of disease activity? *Ann Allergy Asthma Immunol*. 2009;102:532–534.
- [25] Goto T, Morioka J, Inamura H, et al. Urinary eosinophil-derived neurotoxin concentrations in patients with atopic dermatitis: a useful clinical marker for disease activity. *Allergol Int*. 2007;56:433–438.
- [26] Ulfman LH, Joosten DP, van der Linden JA, Lammers JW, Zwaginga JJ, Koenderman L. IL-8 induces a transient arrest of rolling eosinophils on human endothelial cells. *J Immunol*. 2001;166:588–595.
- [27] Kikuchi I, Kikuchi S, Kobayashi T, et al. Eosinophil trans-basement membrane migration induced by interleukin-8 and neutrophils. *Am J Respir Cell Mol Biol*. 2006;34:760–765.
- [28] Tabata R, Tabata C, Katashima Y, Yasumizu R. Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome. *Int Immunopharmacol*. 2013;16:488–491.
- [29] Wolthers OD. Eosinophil granule proteins in the assessment of airway inflammation in pediatric bronchial asthma. *Pediatr Allergy Immunol*. 2003;14:248–254.
- [30] Bunikowski R, Staab D, Kussebi F, et al. Low-dose cyclosporin A micro-emulsion in children with severe atopic dermatitis: clinical and immunological effects. *Pediatr Allergy Immunol*. 2001;12:216–223.
- [31] Sibbald C, Pope E, Ho N, Weinstein M. Retrospective review of relapse after systemic cyclosporine in children with atopic dermatitis. *Pediatr Dermatol*. 2015;32:36–40.
- [32] Bracke M, Dubois GR, Bolt K, et al. Differential effects of the T helper cell type 2-derived cytokines IL-4 and IL-5 on ligand binding to IgG and IgA receptors expressed by human eosinophils. *J Immunol*. 1997;159:1459–1465.
- [33] Luttmann W, Matthiesen T, Matthys H, Virchow JC Jr. Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor- α on eosinophil activation in vitro. *Am J Respir Cell Mol Biol*. 1999;20:474–480.